Christopher Hite - 06 Aug 2025 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Reporting relationship: EVP & Vice Chairman
Issuer ticker: RPRX
Reported as of: 06 Aug 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Aug 2025, 16:54:48 UTC
Prior SEC filing: 20 May 2025
Next SEC filing: 07 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite

Filing notes and source

Key filing fact

Christopher Hite filed Form 4 for Royalty Pharma plc (RPRX) on 08 Aug 2025.

Key facts

This page summarizes Christopher Hite's Form 4 filing for Royalty Pharma plc (RPRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Aug 2025, 16:54.

Change

Previous filing in this sequence was filed on 20 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001814238 Primary reporting owner

Hite Christopher

Relationship: EVP & Vice Chairman
Address: C/O ROYALTY PHARMA PLC, 110 E. 59TH STREET, NEW YORK
Signature: /s/ Sean Weisberg, as Attorney-in-Fact for Christopher Hite
Signature date: 08 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RPRX transaction

Class A Ordinary Shares

Award

Transaction value: $0
Shares: +3,696
Change %: +0.57%
Price: $0.000000
Shares after: 652,342
Date: 06 Aug 2025
Ownership: By SCH Investment Partners LLC
Footnotes: F1

RPRX holding

Class A Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 70,000
Date: 06 Aug 2025
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects the exempt acquisition by the Reporting Person pursuant to Rule 16b-3 of Class A Ordinary Shares of the Issuer in connection with the settlement of Equity Performance Awards.